Rx Product News (August 2016)
Read about the new Rx Products featured in August.
MARKETED BY: Boehringer Ingelheim Pharmaceuticals, Inc
INDICATION: The FDA has approved Jentadueto, a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination product, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. The starting dose of Jentadueto should be individualized based on the patient’s current regimen. The maximum recommended dose is 2.5 mg linagliptin/1000 mg metformin twice daily.
DOSAGE FORM: Tablets (linagliptin/metformin hydrochloride): 2.5/500, 2.5/850, and 2.5/1000 mg
FOR MORE INFORMATION: hcp.jentadueto.com
TEFLAROMARKETED BY: Allergan
INDICATION: The FDA has approved Teflaro (ceftaroline fosamil), a cephalosporin antibacterial, for pediatric patients 2 months of age and older for the treatment of acute bacterial skin and skin structure infections, as well as community-acquired bacterial pneumonia. See the full prescribing information for the recommended dosage.
DOSAGE FORM: Injection: 600 mg or 400 mg of sterile ceftaroline fosamil powder in single-use 20-mL vials. The powder is constituted and further diluted for IV injection.
FOR MORE INFORMATION: teflaro.com
CINQAIRMARKETED BY: Teva Respiratory, LLC
INDICATION: The FDA has approved Cinqair (reslizumab), an interleukin-5 antagonist monoclonal antibody (IgG4 kappa), for add-on maintenance treatment of patients with severe asthma who are 18 years and older, and with an eosinophilic phenotype. Cinqair is for intravenous (IV) infusion only; do not administer as an IV push or bolus. Cinqair should be administered in a health care setting by a health care professional prepared to manage anaphylaxis. The recommended dosage is 3 mg/kg once every 4 weeks by IV infusion over 20 to 50 minutes.
DOSAGE FORM: Injection: 100 mg/10 mL (10 mg/mL) solution in single-use vials
FOR MORE INFORMATION: cinqair.com
OPDIVOMARKETED BY: Bristol-Myers Squibb
INDICATION: The FDA has approved Opdivo (nivolumab) for the treatment of patients with classical Hodgkin lymphoma who have relapsed or progressed after autologous hematopoietic stem cell transplantation and posttransplantation brentuximab vedotin (Adcetris) treatment. The recommended dosage for this indication is 3 mg/kg every 2 weeks.
DOSAGE FORM: Injection: 40 mg/4 mL and 100 mg/10 mL in a single-use vial
FOR MORE INFORMATION: opdivo.com